Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Renier J. Brentjens, P. Maslak et al.|Science Translational Medicine|2014Cited by 2.5k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to dateJae H. Park, Renier J. Brentjens|Blood|2016Cited by 398
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Sham Mailankody, Andrea Knežević et al.|Blood Advances|2020Cited by 264